miguel angel
02-07-2009, 10:21 AM
"It gives a nice little rundown on GNVC's platform and also some potential market opportunities such as the impaired hearing market that is estimated to be at least $6B/year in which there are currently NO competing drugs on the market currently.
Large Market Opportunity.
According to the National Institute on Deafness and Other Communication Disorders, approximately 28 million Americans have a hearing impairment. Even with the most conservative estimates, this represents an opportunity of at least $6 billion.
Positive Results For Hearing Loss & Balance Disorders.
The underlying adenovector delivery technology has been proven safe in thousands of patients across a range of diseases and proof of concept of TherAtoh has been established in multiple preclinical models. The program is positioned to be quickly advanced into the clinic.
TherAtoh
TherAtoh Atonal Therapy is a product concept to restore hearing or balance function through the regeneration of critical cells of the inner ear. Hearing and Balance require specialized cells of the inner ear called sensory hair cells. During embryonic development a gene termed atonal (ATOH) induces the generation of these cells. GenVec has shown preclinically that the production of the ATOH protein results in the formation of new inner ear sensory hair cells, and the restoration of hearing and balance function.
TherAtoh Atonal Therapy – Validated Science; Untapped Market
Atonal Therapy is a product concept to restore hearing or balance function through the regeneration of critical cells of the inner ear. Hearing and Balance require specialized cells of the inner ear called sensory hair cells. During embryonic development a gene termed atonal (ATOH) induces the generation of these cells. GenVec has shown preclinically that the production of the ATOH protein results in the formation of new inner ear sensory hair cells, and the restoration of hearing and balance function. TherAtoH is an adenovector product delivering the human atonal gene (Hath1) to trigger the production of therapeutic proteins by cells in the inner ear.
Addresses Unmet Medical Needs – There are no drug therapies available to treat hearing loss or balance disorders.
This investigational drug is being developed to improve the treatment of inner ear disorders including hearing loss and balance function disorders. According to the National Institute on Deafness and Other Communication Disorders, approximately 28 million Americans have a hearing impairment. Even with the most conservative estimates, this represents an opportunity of at least $6 billion. TherAtoh therapy could be explored for patient segments including those with hearing loss caused by exposure to excessive noise or other trauma, aging, and diseases and infections or their treatment (also in pediatric patients). These segments total approximately 24 million patients. In the United States alone, it is estimated that 5-10% of the population suffers from balance loss and there is little available treatment. The cost of medical care for patients with balance disorders has been estimated to exceed $1 billion per year.
Program is de-risked - The underlying adenovector delivery technology has been proven safe in thousands of patients across a range of diseases and proof of concept of TherAtoh has been established in multiple preclinical models. The program is positioned to be quickly advanced into the clinic".
link: http://messages.finance.yahoo.com/Stocks_(A_to_Z)/Stocks_G/threadview?m=tm&bn=7976&tid=48975&mid=48976&tof=1&off=1
Large Market Opportunity.
According to the National Institute on Deafness and Other Communication Disorders, approximately 28 million Americans have a hearing impairment. Even with the most conservative estimates, this represents an opportunity of at least $6 billion.
Positive Results For Hearing Loss & Balance Disorders.
The underlying adenovector delivery technology has been proven safe in thousands of patients across a range of diseases and proof of concept of TherAtoh has been established in multiple preclinical models. The program is positioned to be quickly advanced into the clinic.
TherAtoh
TherAtoh Atonal Therapy is a product concept to restore hearing or balance function through the regeneration of critical cells of the inner ear. Hearing and Balance require specialized cells of the inner ear called sensory hair cells. During embryonic development a gene termed atonal (ATOH) induces the generation of these cells. GenVec has shown preclinically that the production of the ATOH protein results in the formation of new inner ear sensory hair cells, and the restoration of hearing and balance function.
TherAtoh Atonal Therapy – Validated Science; Untapped Market
Atonal Therapy is a product concept to restore hearing or balance function through the regeneration of critical cells of the inner ear. Hearing and Balance require specialized cells of the inner ear called sensory hair cells. During embryonic development a gene termed atonal (ATOH) induces the generation of these cells. GenVec has shown preclinically that the production of the ATOH protein results in the formation of new inner ear sensory hair cells, and the restoration of hearing and balance function. TherAtoH is an adenovector product delivering the human atonal gene (Hath1) to trigger the production of therapeutic proteins by cells in the inner ear.
Addresses Unmet Medical Needs – There are no drug therapies available to treat hearing loss or balance disorders.
This investigational drug is being developed to improve the treatment of inner ear disorders including hearing loss and balance function disorders. According to the National Institute on Deafness and Other Communication Disorders, approximately 28 million Americans have a hearing impairment. Even with the most conservative estimates, this represents an opportunity of at least $6 billion. TherAtoh therapy could be explored for patient segments including those with hearing loss caused by exposure to excessive noise or other trauma, aging, and diseases and infections or their treatment (also in pediatric patients). These segments total approximately 24 million patients. In the United States alone, it is estimated that 5-10% of the population suffers from balance loss and there is little available treatment. The cost of medical care for patients with balance disorders has been estimated to exceed $1 billion per year.
Program is de-risked - The underlying adenovector delivery technology has been proven safe in thousands of patients across a range of diseases and proof of concept of TherAtoh has been established in multiple preclinical models. The program is positioned to be quickly advanced into the clinic".
link: http://messages.finance.yahoo.com/Stocks_(A_to_Z)/Stocks_G/threadview?m=tm&bn=7976&tid=48975&mid=48976&tof=1&off=1